Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | MAOB | P27338 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | CCR6 | P51684 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6836598 | 1.00 | LMNA (0.56) | LMNASMN1; SMN2MAOBMAPTHTT | |
| SCHEMBL11768167 | 0.85 | ALDH1A1 (0.50) | LMNASMN1; SMN2MAOBMAPTHTT | |
| SCHEMBL11768170 | 0.85 | ALDH1A1 (0.50) | LMNASMN1; SMN2MAOBMAPTHTT | |
| SCHEMBL11283271 | 0.84 | F3 (0.57) | LMNASMN1; SMN2MAOBMAPTHTT | |
| SCHEMBL11283267 | 0.84 | F3 (0.57) | LMNASMN1; SMN2MAOBMAPTHTT | |
| SCHEMBL2266594 | 0.83 | CYP1A2 (0.56) | LMNASMN1; SMN2MAOBMAPTALDH1A1 | |
| SCHEMBL2266597 | 0.83 | CYP1A2 (0.56) | LMNASMN1; SMN2MAOBMAPTALDH1A1 | |
| SCHEMBL9353382 | 0.82 | TDP1 (0.59) | LMNASMN1; SMN2MAOBMAPTHTT | |
| SCHEMBL9353385 | 0.82 | TDP1 (0.59) | LMNASMN1; SMN2MAOBMAPTHTT | |
| SCHEMBL765933 | 0.82 | HCAR2 (0.59) | LMNASMN1; SMN2MAOBMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2822938-B1 | RODENTICIDAL NORBORMIDE ANALOGUES | LANDCARE RES NEW ZEALAND LIMITED (NZ) | 2019-07-03 | — | — | EP | disclosed |
| US-9198420-B2 | Rodenticidal norbormide analogues | LANDCARE RESEARCH NEW ZEALAND LIMITED (NZ) | 2015-12-01 | — | — | US | disclosed |
| US-20150025113-A1 | RODENTICIDAL NORBORMIDE ANALOGUES | ANIMAL CONTROL PRODUCTS LIMITED (NZ) | 2015-01-22 | — | — | US | disclosed |
| EP-2822938-A1 | RODENTICIDAL NORBORMIDE ANALOGUES | Landcare Research New Zealand Limited (NZ) | 2015-01-14 | — | — | EP | disclosed |
| WO-2013133726-A1 | RODENTICIDAL NORBORMIDE ANALOGUES | LANDCARE RESEARCH NEW ZEALAND LIMITED (NZ) | 2013-09-12 | — | — | WO | disclosed |
| US-20040181062-A1 | Benzimidazole cyclooxygenase-2 inhibitor | PFIZER INC | 2004-09-16 | — | — | US | disclosed |
| US-6713482-B2 | SUCH AS (E)-1-(2-PYRIDYL)-2-STYRYL-1H-BENZIMIDAZOLE; ANTIINFLAMMATORY AND ANALGESIC AGENTS; PROSTAGLANDIN INHIBITORS | PFIZER INC. | 2004-03-30 | — | — | US | disclosed |
| US-20030013886-A1 | Benzimidazole cyclooxygenase-2 inhibitors | OKUMURA YOSHIYUKI (JP) | 2003-01-16 | — | — | US | disclosed |
| EP-0937722-B1 | Benzimidazole derivatives as cyclooxygenase-2 inhibitors | PFIZER (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6310079-B1 | NON-STEROIDAL ANTIINFLAMMATORY AGENTS | PFIZER INC. | 2001-10-30 | — | — | US | disclosed |
| EP-0937722-A1 | Benzimidazole derivatives as cyclooxygenase-2 inhibitors | PFIZER INC. (US) | 1999-08-25 | — | — | EP | disclosed |
| US-4061587-A | Liquid crystalline cinnamic acid esters | HOFFMANN-LA ROCHE INC. (US) | 1977-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025113-A1 | RODENTICIDAL NORBORMIDE ANALOGUES | CASP7, RANBP1, CASP3 | LMNA 2399/4885SMN1; SMN2 708/4885MAOB 212/4885 |
| US-20030013886-A1 | Benzimidazole cyclooxygenase-2 inhibitors | PTGS1, CBR1, CBR3 | LMNA 3941/4885SMN1; SMN2 3664/4885MAOB 3180/4885 |
| US-20040181062-A1 | Benzimidazole cyclooxygenase-2 inhibitor | PTGS1, CBR1, CBR3 | LMNA 3843/4885SMN1; SMN2 3467/4885MAOB 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.